NBIX
NEUROCRINE BIOSCIENCES INC
Latest close $161.50 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 3 parsed filing(s)| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| JPMorgan Chase / Asset Management CIK0000019617 | Jun 30, 2026 observed Jul 27, 2026 filed · 27d Schedule 13G amendment | Reported accumulation | 6.3M +1.1M | 12.00% 0.00 pts | $168.54 | $176.41 | $161.50 |
| JPMorgan Chase / Asset Management CIK0000019617 | Dec 31, 2025 observed Jan 21, 2026 filed · 21d Initial Schedule 13G | Initial Schedule 13G | 5.2M | 12.00% | $141.83 | $135.41 | $161.50 |
| BlackRock Legacy CIK0001364742 | Dec 31, 2023 observed Jan 23, 2024 filed · 23d Schedule 13G amendment | Earliest Schedule 13G amendment found | 13.6M | 13.90% | $161.50 |